Figure 1From: Patan hospital experience in treating philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukemia patients with gleevec (imatinib mesylate); the first generation specific tyrosine kinase inhibitor Kaplan-Meier of cumulative survival of all patients. This figure shows the cumulative survival of all patients enrolled in GIPAP.Back to article page